<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225312</url>
  </required_header>
  <id_info>
    <org_study_id>NL70503.029.19</org_study_id>
    <nct_id>NCT04225312</nct_id>
  </id_info>
  <brief_title>Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis</brief_title>
  <acronym>NEXT-MS</acronym>
  <official_title>Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stichting MS Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovatiefonds Zorgverzekeraard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple&#xD;
      sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab&#xD;
      infusions. Natalizumab trough concentrations after a 4-weekly interval are high in the large&#xD;
      majority of patients which implies a relative overdose in most patients. The investigators&#xD;
      have demonstrated that efficacy of natalizumab is maintained when the infusion interval is&#xD;
      extended based on natalizumab trough concentrations (personalized extended interval dosing).&#xD;
      This leads to fewer hospital visits, a decrease of healthcare costs and decrease of risk of&#xD;
      complications of natalizumab treatment.&#xD;
&#xD;
      Objective: The objective is to test feasibility and validate safety of personalized extended&#xD;
      interval dosing of natalizumab in a large real-life cohort across the Netherlands.&#xD;
&#xD;
      Study design: Prospective national phase IV natalizumab cohort study.&#xD;
&#xD;
      Study population: All patients, aged 18 years or older, who are currently treated with&#xD;
      natalizumab in the Netherlands for RRMS, with a minimum of 6 consecutive infusions.&#xD;
&#xD;
      Intervention: Patients will receive a personalized extended interval dosing (4-8 weeks) based&#xD;
      on two natalizumab trough concentrations in the standard 4 week interval.&#xD;
&#xD;
      Main study parameters/endpoints: The main study endpoint is the safety (defined by&#xD;
      radiological disease activity) of personalized natalizumab dosing in a large real-life cohort&#xD;
      across the Netherlands. Data will be collected regarding disease activity and disability&#xD;
      progression. A cost analysis will be performed to show the extent of cost reduction. Patients&#xD;
      will be annually followed to assess the influence of personalized dosing on John Cunningham&#xD;
      virus (JCV) conversion, JCV index, incidence of progressive multifocal leukoencephalopathy&#xD;
      and treatment satisfaction and quality of life. The influence of personalized dosing on&#xD;
      pharmacokinetics will be monitored. Furthermore, personalized extended interval dosing will&#xD;
      be studied in a subgroup with the aim to explore lower than previously studied trough values&#xD;
      of natalizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed trial is a national open label phase IV natalizumab cohort study. The large&#xD;
      majority of natalizumab treated RRMS patients in The Netherlands will be asked to participate&#xD;
      in this study by their treating neurologist. The study will start with approximately 15&#xD;
      participating centers and expand the study with amendments of more participating centers. The&#xD;
      study duration is two years, with an extension phase of another two years. This study will&#xD;
      contain a main study group with a control group ,a smaller study subgroup and a historic&#xD;
      control group. Participants will decide in which group they will participate as this is an&#xD;
      open label, non-randomized study. This design was chosen as it was expected that the large&#xD;
      majority of patients wanting a personalized natalizumab treatment for the following reasons.&#xD;
      Other research groups studied personalized and extended dosing of natalizumab treatment, all&#xD;
      indicating that this is a safe approach. A drastic reduction of PML risk with extended&#xD;
      interval dosing causes a growing trend internationally to personalized/extended interval&#xD;
      dosing. Furthermore, there is an increasing wish in patients and physicians for personalized&#xD;
      treatment to increase patient convenience and lowering costs of expensive medication and&#xD;
      healthcare.&#xD;
&#xD;
      For the study subgroup with a lower aim of trough concentration, only completely stable&#xD;
      patients will be included, in this way the patients will be their own control, expecting no&#xD;
      recurrence of disease activity. The latter design is equal to a previous study on&#xD;
      personalized EID. If patients desire a personalized natalizumab treatment and have been&#xD;
      treated with ≥6 consecutive natalizumab infusions, they have the opportunity of entering the&#xD;
      study as a participant of the main PEID study group or the low PEID study group. The main&#xD;
      PEID study group will receive a personalized treatment with the aim of a natalizumab trough&#xD;
      concentration of 10µg/ml. Patients in the low PEID study group have the aim of a natalizumab&#xD;
      trough concentration of 5µg/ml.&#xD;
&#xD;
      If patients do not desire a personalized treatment, they will be asked informed consent for&#xD;
      the use of their patient data and for the questionnaires as the control group. As this&#xD;
      introduces a bias, the main study group will be compared to a historical cohort of Amsterdam&#xD;
      MS Center. Furthermore, the patients of the control group will be asked to donate blood once&#xD;
      for measuring of natalizumab trough concentration and natalizumab antibodies.&#xD;
&#xD;
      As of April 2021, the European Commission has granted marketing authorization for SC&#xD;
      injec-tion of natalizumab. As pharmacokinetics and pharmacodynamics between SC and IV&#xD;
      ad-ministration resulted in comparable trough natalizumab serum concentration and a4-integrin&#xD;
      receptor saturation, patients who desire a switch from IV administration to SC administration&#xD;
      will have the opportunity to continue the study in the same study group.&#xD;
&#xD;
      An interim analysis will be performed after the 100th patient completes the first year of&#xD;
      PEID and after 200 patients complete the first year of PEID.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 3, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective national phase IV natalizumab cohort study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of T2 lesions on brain MRI</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Assessing new/enlarging T2 lesions on brain MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Clinical relapses during personalized extended interval dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability progression during follow-up</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Disability progression measured on the Expanded Disability Status Scale (EDSS); running form 0 (no disability) to 10 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Cost-utility analysis using EuroQol 5D (EQ-5D) and the Work Productivity and Activtiy Impairment Questionnaire (WPAI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>JC virus conversion</measure>
    <time_frame>6 monthly JCV measurement for two years</time_frame>
    <description>Annual conversion rate of the John Cunningham Virus (JCV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Course JC virus index</measure>
    <time_frame>6 monthly JCV measurement for two years</time_frame>
    <description>Course of John Cunningham Virus (JCV) index in JCV positive patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natalizumab wearing-off effect</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Occurrence of the natalizumab wearing-off effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stability of natalizumab trough concentration</measure>
    <time_frame>6 monthly natalizumab trough concentrations for two years</time_frame>
    <description>Long-term stability of natalizumab trough concentration in personalized interval dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient preference</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of patients preferring personalized treatment over standard treatment and percentage staying on personalized treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life: MSIS-29</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Quality of life on the Multiple Sclerosis Impact Scale (MSIS-29)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of treatment: TSQM</measure>
    <time_frame>Baseline, year 1, year 2</time_frame>
    <description>Satisfaction of treatment on the Treatment Satisfaction Questionnaire of Medication (TSQM)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progressive multifocal leukoencephalopathy</measure>
    <time_frame>Trough study completion, an average of 2 years</time_frame>
    <description>Incidence of progressive multifocal leukoencephalopathy</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Personalized extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized dosing based on natalizumab trough concentration with an aim of natalizumab trough concentration of 10mcg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low personalized extended interval dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Personalized dosing based on natalizumab trough concentration with a lower aim of natalizumab trough concentration of 5mcg/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard interval dosing</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients who prefer to stay on standard interval dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historic cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Historic cohort of natalizumab treated patients on standard interval dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Personalized extended interval dosing of natalizumab</intervention_name>
    <description>Personalized extended interval dosing of natalizumab based on natalizumab trough concentration</description>
    <arm_group_label>Low personalized extended interval dosing</arm_group_label>
    <arm_group_label>Personalized extended interval dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard interval dosing</intervention_name>
    <description>Standard interval dosing in control group and historic group</description>
    <arm_group_label>Historic cohort</arm_group_label>
    <arm_group_label>Standard interval dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of relapsing remitting multiple sclerosis according to the 2017 criteria21&#xD;
&#xD;
          -  6 or more consecutive natalizumab infusions&#xD;
&#xD;
          -  18 years or older&#xD;
&#xD;
          -  Agreed to participate (written informed consent)&#xD;
&#xD;
          -  Disease stability (radiological and clinical) ≥ 12 months (only in low personalized&#xD;
             extended interval dosing group)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  High titer natalizumab (&gt;100 arbitrary units (AU)/ml) antibodies&#xD;
&#xD;
          -  Contraindication for frequent magnetic resonance imaging (MRI) (ie, pacemaker or other&#xD;
             contraindicated implanted metal devices, or have claustrophobia that cannot be&#xD;
             medically managed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joep Killestein</last_name>
    <phone>0031 0204441982</phone>
    <email>j.killestein@amsterdamumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zoé van Kempen</last_name>
    <phone>0031 0204442182</phone>
    <email>z.vankempen@amsterdamumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente hospital</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Genugten, Dr.</last_name>
      <email>j.vgenugten@zgt.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Flevoziekenhuis</name>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A Vennegoor, Dr.</last_name>
      <email>avennegoor@flevoziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amsterdam UMC, location VUmc</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Killestein, Dr.</last_name>
      <email>j.killestein@amsterdamumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>N Kalkers, Dr.</last_name>
      <email>n.f.kalkers@olvg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Mostert, Dr.</last_name>
      <email>jmostert@rijnstate.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina hospital Assen</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Kloosterziel, Dr.</last_name>
      <email>mark.kloosterziel@wza.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C van Munster, Dr.</last_name>
      <email>CvanMunster@amphia.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Reinier de Graaf hospital</name>
      <address>
        <city>Delft</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Kragt, Dr.</last_name>
      <email>j.kragt@rdgg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Hospital</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J van Eijk, Dr.</last_name>
      <email>J.Eijkvan@jbz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Slingeland Hospital</name>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C Roosendaal, Dr.</last_name>
      <email>C.Roosendaal@slingeland.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ommelander Hospital Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J Nielsen, Dr.</last_name>
      <email>j.nielsen@ozg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Heersema, Dr.</last_name>
      <email>d.j.heersema@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spaarne gasthuis hospital</name>
      <address>
        <city>Haarlem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Eurelings, Dr.</last_name>
      <email>meurelings@spaarnegasthuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sint-Jansdal Hospital</name>
      <address>
        <city>Harderwijk</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L Oosterveld, Dr.</last_name>
    </contact>
    <contact_backup>
      <email>DW.frijlink@stjansdal.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>L Sinnige, Dr.</last_name>
      <email>l.g.f.sinnige@mcl.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alrijne Hospital</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Hoitsma, Dr.</last_name>
      <email>ehoitsma@alrijne.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maasstad hospital</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L van Rooij, Dr.</last_name>
      <email>rooijl@maasstadziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G van Dijk, Dr.</last_name>
      <email>g.v.dijk@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>B Wokke, Dr.</last_name>
      <email>b.wokke@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medical Center</name>
      <address>
        <city>The Hague</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>M Tonk, Dr.</last_name>
      <email>m.tonk@haaglandenmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elizabeth tweesteden Hospital</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Arnoldus, Dr.</last_name>
      <email>e.arnoldus@etz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Bouvy, Dr.</last_name>
      <email>wbouvy@diakhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Hoogervorst, Dr.</last_name>
      <email>e.hoogervorst@antoniusziekenhuis.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>E Zeinstra, Dr.</last_name>
      <email>ZEINSTRAE@isala.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 3, 2020</study_first_submitted>
  <study_first_submitted_qc>January 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Zoé van Kempen</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Natalizumab</keyword>
  <keyword>Extended interval dosing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

